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Abstract 
Background: Antiretroviral treatment (ART) can decreased the incidence of HIV dementia, but milder 
cognitive impairment may not resolve when patients receive ART. In Indonesia, cognitive screening of 
HIV patients is not routinely performed before starting ART. Here we assess cognitive impairment in 
ART- naïve HIV patients beginning treatment in Jakarta. Methods: This is a cross sectional study with 
inclusion criteria: HIV positive, ART naïve, CD4 T-cells below 200 cells/uL, Karnofsky Performance 
Score (KPS) above 70. HIV-associated neurocognitive disorder (HAND) was defined by performance 
at least 1 Standard Deviation (SD) below the mean of demographically adjusted normative scores 
in at least two cognitive areas. Results: We studied 82 subjects with median (range) age 31 (19-48) 
years. Fifty six subjects (68%) were males. HAND was found in 42 subjects (51%). Eight subjects 
(19%) had impairment in 4 domains, 15 subjects (36%) in 3 and 19 (45%) in 2. The most common 
domain affected was memory (63%).
Conclusion: Our results show the prevalence of HAND is high among HIV naïve patients in Jakarta. 
This establishes the need for screening of cognitive function before initiating ART.
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INTRODUCTION
HIV infection affects many systems including the 
central nervous system, and patients may display 
cognitive impairment, headache, seizures and/
or manifestations of space occupying lesions.1 
Cognitive impairment can emerge in the early stages 
of HIV infection. In 2007, the National Institute 
of Mental Health, with the National Institute of 
Neurological Disease and Stroke, proposed revised 
nomenclature for HIV neurocognitive disorders, 
known as the Frascti Criteria. HIV-associated 
neurocognitive disorder (HAND) was categorized 
into 3 groups; HIV-associated asymptomatic 
neurocognitive impairment (ANI), HIV-associated 
mild neurocognitive disorder (MND) and HIV-
associated dementia (HAD). Under these criteria, 
HAND is defined by performance at least 1 
standard deviation (SD) below the mean of 
demographically adjusted normative scores in at 
least two cognitive areas.2
 Antiretroviral treatment (ART) can reduce 
the incidence of HIV dementia3 and increase 
the quality of life, but less severe cognitive 
impairment may persist throughout a patient’s 
life.3In 2013 totally there were 29,0376  HIV 
cases and 5,608 AIDS cases in Indonesia.5 Most 
(70%) were aged 25-49 years, which are the 
productive years in a person’s life. However ART 
is not available for all patients in need. Thus 
many patients begin treatment with advanced HIV 
disease5, some of whom may have neurological 
deficits. Unfortunately cognitive screening is not 
routinely performed, so the extent of the problem 
is unclear. The aim of this study was to determine 
the prevalence of cognitive impairment in ART- 




We present a cross sectional study of HIV patients 
(n=82), aged 18-50 years, attending the HIV 
clinic at Cipto Mangunkusumo Hospital, Jakarta, 
between March 2013 and March 2014. Inclusion 
criteria included HIV infection documented by 
ELISA, ART naïve, CD4 T-cells below 200 cells/
uL, Karnofsky Performance Score (KPS) above 
70. Exclusion criteria included active or known 
past opportunistic infection of the central nervous 
system (CNS), history of chronic neurological 
disease, head trauma, major depression, other 
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psychiatric disease, antipsychotic treatment, 
pregnancy, breast feeding and physical deficits 
that would interfere with cognitive assessment 
(confirmed by examination). The study procedure 
was approved by Faculty of Medicine, University 
of Indonesia and Cipto Mangunkusumo Hospital 
ethics committees. Written consent was obtained 
from each subject after they understood the 
purpose and agreed to join the study. Subjects also 
completed blood counts and tests for anti-hepatitis 
C antibody, plasma HIV RNA load, chest X-ray 
and sputum acid bacilli smear. 
Neurocognitive assessments
Demographic data and clinical history were 
collected by interviewing subjects using a 
questionnaire. This included date of birth, gender, 
education level, occupation, HIV transmission 
route, smoking habit, history of drug use, 
history of neurological illness and medications 
taken. Depression was assessed using Hamilton 
depression rating scale.Cognitive examinations 
were performed using established tools covering 
several cognitive domains6 (Table 2) by a trained 
physician in a quiet room. 
 Normative values were taken from healthy 
subjects whose age and education were similar 
to the study subjects. Inclusion criteria for the 
healthy subjects included age 18-50 years and 
a normal Mini Mental State Examination score. 
Exclusion criteria included KPS less than 70, 
neurological disease (epilepsy, stroke, brain 
infection and brain tumor), excessive HIV risk 
(eg: drug use, prostitution), history of head 
injury, major depression, and disabilities likely 
to interfere with cognitive tests.
Statistical analyses
The results of cognitive examination from each 
area were transformed into Z scores by subtracting 
the test result from themean of normative value 
then dividing by the standard deviation of the 
normative value. Z scores for the Grooved 
Pegboard test were obtained from the mean of 
Z score of dominant and non-dominant hand. 
Cognitive function was defined as abnormal 
if there were 2 areas of cognitive domainwith 
Z scores less than 1.2 Statistical analyses were 
performed using SPSS 17.0.Sex, education level, 
transmission route, hepatits C co-infection and 
pulmonary tuberculosis (TB) were presented 
as numbers of cases by percentage. Age, CD4 
T-cell counts and plasma RNA levels were not 
normally distributed (Kolomogorov Smirnov test) 
and so are presented as median (range). Mean 
rank difference of these Z-score between HIV+ 
subjects and healthy control were analyzed using 
Mann-Whitney U tests. The effect size of the HIV 
status was also calculated using the Z scores, from 
U tests divided by the square root of the number 
of subjects. Categorical data were assessed using 
chi-square test (education level, sex, transmission 
route and hepatitis C co-infection). Age, plasma 




From March 2013 until March 2014, 82 HIV 
patients were eligible for this study (Table 1). 
Their median (range) age was 31 (19-48) years 
and 56 (68%) were males. The most common 
transmission route was heterosexual contact 
(50 subjects, 61%). The CD4 T-cell count was 
lowest in drug users (48 cells/ul). Anti-hepatitis 
C antibody and pulmonary TB were found in 
41 (50%) and 18 (22%) subjects respectively. 
Subjects with Hepatitis C co-infection had lower 
median CD4 T-cell counts (30 vs 74 cells/uL, 
p=0.017). The median (range) age of healthy 
controls was 30.5 (18-50) years. The number of 
females was higher than in the HIV+ group, but 
their age and education were similar.
Neurocognitive performance
The raw scores of neurocognitive results 
transformed into Z-scores are shown in Table 2. 
In general, HIV subjects’ results were inferior to 
those of healthy controls. There were significant 
differences in Forward Digit Span (FDS), 
Backward Digit Span (BDS), Animal Naming 
Test (ANT), Grooved Pegboard and assessments 
of memory. The clearest differences arose 
with delayed recall from Rey Auditory Verbal 
Learning Test in trial 7 (RAVLT-7) and Learning 
over training.The effect size was medium in the 
attention domains (FDS and BDS) and fluency 
(ANT). Based on cognitive domains, the most 
common impairment was in memory (63%), 
followed by fluency (40%) (Figure 1). There were 
27 (33%) subjects with impairment in only 1 
domain, 19 (23%) with 2 domains, 15 (18%) with 
3 domains and 8 (10%) with 4 or more domains. 
The mean of Z total score of HIV subjects was 
-1.00 (0.096) with 20 (24%) subject having a 
score less than -1 and 12 (15%) of subjects less 
than -2. 
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 There were 42 subjects (51%) who had 
impairment in 2 or more domains with Z score 
1 SD below normative scores (HAND) with 
OR=16.2 (p<0.001; 95% CI 5.9-44). After 
adjustment for education, this association was still 
significant (p<0.001; OR=15.5, 95%CI 5.6-43).
Risk Factors for HAND
Among 42 subjects with HAND, 8 subjects (19%) 
had 4 domains impaired, 15 subjects (36%) had 3 
domains and 19 (45%) had 2 domains. The most 
common domain affected was memory (88%). 
There were significant differences in the education 
level between HAND and non-HAND patients 
Table 1:  Characteristics of patients and controls
Parameter Median (range), unless otherwise stated p
  HIV+ Healthy control
Age, years 31 (19-48) 30 (18-50) 0.48
Males, n(%) 56 (68) 39 (48) 0.01





	 •		Unknown		 2	(2.4) 
CD4	T-cells/uL	 62	(2-199)  
Plasma	HIV	RNA	(log	10),	copies/mL	 5.1	(2.6-6.6)  
Pulmonary	TB	co-infection,	n(%)	 41	(50)  
Hepatitis	C	co-infection,	n(%)	 18	(22)
Table 2: Neurocognitive test results ( Z-Scores ) for HIV patients
Ability domain Cognitive test Z Score Result  P* r
  (Median, range)
Attention  Forward Digit Span (FDS) -0.80 (-2.8-1.2) 0.000 0.44 
 Backward Digit Span (BDS) -0.93 (-3.7-2.2) 0.000 0.49
Fluency Animal Naming Test (ANT) -0.67 (-0.78-2.9) 0.000 0.49
Executive Trail Making A (secs) 0.23 (-6.4-1.6) 0.72 0.04 
Function  Trail Making B (secs) 0.10 (-12-1.9) 0.34 0.10
Fine Motor Grooved Pegboard dominant hand (secs) -0.28 (-20-4.2) 0.002 0.34 
Skills Grooved Pegboard non-dominant hand (secs -0.09 (-2.2-8.8) 0.017 0.26
Memory Rey	Auditory	Verbal	Learning	Test	    
 Immediate	Recall	(RAVLT-1)*	 -0.47	(-3.0-1.5)	 0.000	 0.40 
 Delayed	Recall	(RAVLT-7)**	 -3.33	(-14-0.55)	 0.000	 0.99 
 Learning	over	training***	 -1.24	(-8.3-1.8)	 0.000	 0.71
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(p=0.005). Lower education was associated 
with lower neurocognitive performance. Risk 
factor analyses for each domain showed that the 
education effect was pronounced in the fluency 
(p<0.001), executive function (p=0.04) and fine 
motor skill (p=0.05) domains (Table 3). The CD4 
T-cell counts and plasma HIV RNA were similar 
in HAND and non-HAND patients (66.5 cells/
uL vs 56.5 cells/uL). Median CD4 T-cell counts 
were lowest (63 cells/uL) among subjects with 
attention impairment compared to those with 
defects in other domains.
DISCUSSION
Patients were compared with healthy controls 
matched by demographic characteristics and 
ethnicity to theHIV+ subjects. Controls and 
patients were recruited from Cipto Mangunkusumo 
hospital area and were similar in age.However the 
age range was limited so there were no detectable 
effects of age on cognitive impairment.
 In most cognitive domains, HIV subjects were 
significantly inferior to healthy controls. The 
exception is inthe trail making tests (executive 
function). There were smaller differences in fine 
motor speed performance between HIV+ subjects 
and healthy control. This agrees with Groove 
Peg Board data from Cameroon showing a small 
effect size between HIV+ and HIV- subjects.7 
Robertson et al found no significant different in 
fine and gross motor tests between Ugandan HIV+ 
and healthy controls, but these authors found 
impairment in subjects with AIDS dementia. This 
small difference in motor speed between patients 
and controls supportsthe current finding.8
 The prevalence of HAND among Indonesian
ART naïve HIV patients in our cohort was 51% 
(95% CI 34-56). This number was higher than was 
observed in a study by the Asia Pacific Neurology 
Network (APNAC) that included Indonesia as 
one study site. The APNAC study found the 
prevalence of cognitive impairment in Asia Pacific 
Region was 12% (Indonesia had 11%).9 However 
the APNAC study included patients responding 
to ART, whilst our study focused on ART naïve 
patients. Nicholass et al. found the prevalence of 
cognitive impairment in young ART naïve patients 
(18-24 year-old) was 67%10, whilst Hasbun et al. 
observed cognitive impairment in 75% of patients 
aged 22-64 years.11 These individuals are slightly 
older than our patients. This suggests that the 
cognitive impairment seen in our study was not 
due to older age effect.
 Subject with less than 9 years of education had a 
higher risk of developing HAND (OR=3.2).  Wang 
et al. also reported that HAND was more prevalent 
in older subjects with lower education level.12 We 
found no relationship between HAND and CD4 
T-cell counts. Several studies also have failed to 
find the relationship between HAND and CD4 
T-cell counts.13-15 However Marcotte et al. found a 
relationship between nadir CD4 T-cell counts early 
after seroconversion and progression to cognitive 
impairment. Although 22% of subjects were taking 
ART, progression to cognitive impairment was 
similar in subjects receiving treatment and those 
who never treated.14
 There were no significant associations between 
plasma HIV RNAand HAND, but HIV RNA levels 
were marginally higher in HAND subjects. Other 
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studies also failed to show the correlation between 
plasma HIV RNA and cognitive impairment15,17, 
but CSF viral load appears to correlate with 
cognitive function and CNS dysfuction.18,19
 The most common impairment in our study 
was memory (63%), followed by fluency (40%) 
and attention (38%).Similarly Gupta et al. showed 
60% subject had mild to moderate cognitive 
impairment in fluency and memory.20 Functional 
MRI showed greater activation in frontal lobe in 
HIV patients while performing complex tasks, 
compared to healthy controls. This indicated the 
use of more brain reserve due to fronto-striatal 
brain injury affecting the regions responsible for 
attention and working memory.21
 Our results show that HAND is common among 
ART naïve HIV patients in Jakarta. This shows 
the need of cognitive function screening before 
initiating ART. Prospective studies are also needed 
to monitor cognitive changes after ART.
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